EGFR and lung cancer: In the past decade, lung cancer treatments have generally focused on targeted therapies such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) fusion protein inhibitors.